Peptide021(P021) manufacturers
- P21 with adamantane
-
- $290.00
-
2026-09-18
- CAS:1246751-68-7
- Min. Order: 1kit
- Purity: 99.99%
- Supply Ability: 1000000 kit
- P21 (P021)
-
- $9.00
-
2026-09-17
- CAS:1246751-68-7
- Min. Order: 10VIAL
- Purity: 99.9%
- Supply Ability: 10000
- P21 (P021)
-
- $9.00
-
2026-09-17
- CAS:1246751-68-7
- Min. Order: 10VIAL
- Purity: 99.9%
- Supply Ability: 10000
|
| | Peptide021(P021) Basic information |
| Product Name: | Peptide021(P021) | | Synonyms: | L-Leucinamide, N-acetyl-L-α-aspartylglycylglycyl-N-[3-(aminocarbonyl)tricyclo[3.3.1.13,7]dec-1-yl]-;Peptide021(P021);L-Leucinamide P21 Peptides;P21 (P021) | | CAS: | 1246751-68-7 | | MF: | C27H42N6O8 | | MW: | 578.66 | | EINECS: | | | Product Categories: | | | Mol File: | 1246751-68-7.mol |  |
| | Peptide021(P021) Chemical Properties |
| Boiling point | 1061.4±65.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | pka | 4.23±0.10(Predicted) | | InChIKey | ZBTMPXAMODQBPM-ZKHAZHQOSA-N | | SMILES | C(N)(=O)[C@H](CC(C)C)N(C(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(C)=O)C12CC3CC(CC(C(N)=O)(C3)C1)C2 |
| | Peptide021(P021) Usage And Synthesis |
| Uses | Derived from amino acids 139–164 of the C-terminus of the full-length p21 protein, the Peptide021(P021) interferes with proliferating cell nuclear antigen (PCNA) function and lacks organized structure in its free form[1][2]. The p21C2 peptide serves as a precursor to analyze whether S phase is inhibited by microinjection[1]. | | References | [1] Chen, J., Peters, R., Saha, P., Lee, P., Theodoras, A., Pagano, M., Wagner, G., & Dutta, A. (1996). A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Research, 24 9, 1727–1733. https://doi.org/10.1093/nar/24.9.1727
[1] Walker, L. R., Ryu, J. S., Perkins, E., McNally, L. R., & Raucher, D. (2014). Fusion of cell-penetrating peptides to thermally responsive biopolymer improves tumor accumulation of p21 peptide in a mouse model of pancreatic cancer. Drug Design, Development and Therapy, 1649–1658. https://doi.org/10.2147/DDDT.S60451 |
| | Peptide021(P021) Preparation Products And Raw materials |
|